OKDAVNasdaq HelsinkiPharmaceutical RetailersIFRS · EUR

Oriola Oyj

Oriola is a Nordic pharmaceutical company that operates in the distribution and wholesale of pharmaceuticals and health products across Finland and Sweden. The company focuses on providing logistics services, dose dispensing, and advisory services to healthcare providers and pharmacies. Oriola has strengthened its market position through strategic acquisitions and investments in advanced distribution centers. The company is committed to sustainability, having set ambitious climate targets validated by the Science Based Targets initiative.

Revenue1,906m EUR
+13.5 %y/y
Operating profit (EBIT)2.6m EUR
−80.9 %y/y
EBIT margin0.1%
−0.7 ppy/y
Net income-27.2m EUR
−35.3 %y/y
Free cash flow56.7m EUR
+57.9 %y/y

Fiscal year 2025 · change from previous year

Development 2021–2025

-50005001,0001,5002,000m EUR2021: 1,882 m EUR2021: EBIT 21 m EUR20212022: 1,516 m EUR2022: EBIT 7.6 m EUR20222023: 1,494 m EUR2023: EBIT -5.3 m EUR20232024: 1,680 m EUR2024: EBIT 14 m EUR20242025: 1,906 m EUR2025: EBIT 2.6 m EUR2025TTM 2026: EBIT 4.5 m EURTTM4.5
RevenueOperating profit (EBIT)TTM = last 12 months, not a full fiscal year

Business

Share of revenue
Distribution60 %

Includes pharmaceutical logistics and dose dispensing services.

Wholesale30 %

Covers OTC products, special licensed medicines, and parallel import.

Advisory Services10 %

Offers consulting and data solutions for pharmaceutical companies.

Customers

Oriola serves a diverse range of customers including pharmacies, hospitals, veterinarians, and other healthcare providers in Finland and Sweden. The company provides dose dispensing services to both private and public healthcare sectors, enhancing patient safety with pre-dispensed medications. Oriola's wholesale segment caters to retail and online markets, ensuring the availability of health and wellness products. The advisory services segment supports pharmaceutical companies with market entry and regulatory compliance in the Nordic region.

Pharmacies

Purchase logistics and wholesale services for efficient supply.

Hospitals

Rely on Oriola for dose dispensing and pharmaceutical logistics.

Veterinarians

Source special licensed medicines and OTC products.

Healthcare Providers

Use advisory services for regulatory compliance.

Strategy

Oriola's strategic priorities include reinforcing customer focus, expanding value-adding services, and improving operational efficiency. The company is investing in advanced distribution infrastructure and IT systems to support growth and sustainability goals. Oriola aims to strengthen its position in the Nordic advisory market through acquisitions and partnerships. The focus on sustainability is reflected in ambitious climate targets and investments in energy-efficient facilities.

Customer FocusShort term

To enhance service delivery and customer satisfaction.

Infrastructure InvestmentMedium term

To support growth and operational efficiency.

SustainabilityLong term

To align with climate targets and reduce emissions.

Geography

Q4/2025

Oriola operates primarily in Finland and Sweden, with a strong presence in the Nordic pharmaceutical distribution market. The company has significant market shares in both countries, with 42% in Sweden and 46% in Finland. Oriola's logistics and distribution centers are strategically located to support efficient operations across these regions. The company's recent investments in a new distribution center in Järvenpää, Finland, aim to enhance capacity and sustainability.

Sweden64 %
Finland30 %
Other countries6.6 %

Share of the revenue the company reports by geography.

Risks

Oriola faces several risks including regulatory changes in the pharmaceutical industry, supply chain disruptions, and geopolitical uncertainties. The company's operations are subject to strict regulations, and any non-compliance could impact its business. Supply chain constraints and cost inflation pose challenges to profitability. Additionally, cybersecurity threats and market volatility could affect operations and financial performance.

Sorted by severity
LowMediumHighLowMediumHighImpact →Likelihood →Supply Chain Disruptions1Regulatory Changes2Geopolitical Uncertainties3Cybersecurity Threats4
Impact is the risk’s severity and likelihood how probable it is over the next few years, both assessed from the company’s reports. Numbers match the list.
  1. Supply Chain DisruptionsImpact: CriticalLikelihood: Low

    Constraints affecting product availability.

  2. Regulatory ChangesImpact: HighLikelihood: Medium

    Strict regulations in pharmaceutical distribution.

  3. Geopolitical UncertaintiesImpact: HighLikelihood: Medium

    Influencing market conditions and operations.

  4. Cybersecurity ThreatsImpact: HighLikelihood: Medium

    Potential impact on critical operations.

Accounting

Judgemental items
Revenue Recognition

Affects quarterly financial results.

Impact: medium

Lease Accounting

Impacts reported liabilities and expenses.

Impact: medium

Estimates and Provisions

Related to regulatory compliance and legal proceedings.

Impact: high

Publicly listed companies with a comparable business focus.

Last updated: 24/09/2026